Techniques in Regional Anesthesia & Pain Management
Volume 14, Issue 2 , Pages 75-85 , April 2010

Nonopioid analgesic pipeline: Pharmacology, safety, tolerability, and potential advantages over established agents

  • Rajpreet Bal, MD
    • ,
  • Lakesha Legree, MD
    • ,
  • Sudhir Diwan, MD

      Affiliations

    • Corresponding Author InformationAddress reprint requests and correspondence: Sudhir Diwan, MD, Weill Cornell Medical College, Department of Pain Medicine and Anesthesiology, 525 East 68th Street, New York, NY 10065

References 

  1. Ropper AH, et al. Pain. In:  Ropper AH,  Samuels MA editor. Adams and Victor's Principles of Neurology. (ed 9). New York: McGraw-Hill; 2009;Chapter 8
  2. Attal N, Bouhassira D. Mechanisms of pain in peripheral neuropathy. Acta Neurol Scand Suppl. 1999;173:12–24discussion 48-52
  3. Fauci A, et al. Pain: Pathophysiology and management. In:  Fauci AS,  Braunwald E,  Kasper DL, et al. editor. Harrison's Principles of internal medicine. (ed 17). New York: McGraw-Hill; 2008;Chapter 12
  4. Morgan GE, et al. Pain management. In:  Morgan GE,  Mikhail MS,  Murray MJ editor. Clinical Anesthesiology. New York: McGraw-Hill; 2006;Chapter 18
  5. Kroenke K, Krebs EE, Bair MJ. Pharmacotherapy of chronic pain: A synthesis of recommendations from systematic reviews. Gen Hosp Psychiatry. 2009;31:206–219
  6. Sternbach RA. Survey of pain in the United States: The Nuprin pain (Report). Clin J Pain. 1986;2:49–53
  7. Stewart WF, Ricci JA, Chee E, Morganstein D, Lipton R. Lost productive time and cost due to common pain conditions in the US workforce. J Am Med Assoc. 2003;290:2443–2454
  8. Tremon-Lukats IW, Megeff C, Backonja MM. Anticonvulsants for neuropathic pain syndromes: Mechanisms of action and place in therapy. Drugs. 2000;60:1029–1052
  9. Hyllested M, Jones S, Pedersen JL, Kehlet H. Comparative effect of paracetamol, NSAIDs, or their combination in post operative pain management: A qualitative review. Br J Anaesth. 2002;88:199–214
  10. Shaojun . Clinical use and pharmacologic properties of selective COX-2 inhibitor. Eur J Clin Pharmacol. 2008;64:233–252
  11. Pincus . Patient preference for placebo, acetaminophen (paracetamol) or celecoxib efficacy studies (PACES): Two randomised, double blind, placebo controlled, crossover clinical trials in patients with knee or hip osteoarthritis. Ann Rheum Dis. 2004;63:931–939
  12. Katzung BG, Masters SB, Trevor AJ. Drugs that act in the central nervous system, in Basic and Clinical Pharmacology. (ed 11). New York: McGraw-Hill; 2009;Section 5
  13. Campbell FG, et al. Clinical trial of carbamazepine (Tegretol) in trigeminal neuralgia. J Neurosurg Neurol Psychiatry. 1966;29:265–267
  14. Killian JM, Fromm GH. Carbamazepine in the treatment of neuralgia. Arch Neurol. 1968;19:129–136
  15. Rull JA, Quibrera R, González-Millan H, et al. Symptomatic treatment of peripheral diabetic neuropathy with carbamazepine: Double-blind crossover study. Diabetologia. 1969;5:215–220
  16. Nicol C. A four year double blind randomized study of Tegretol in facial pain. Headache. 1969;9:54–57
  17. McKellar G, Singh G. Celecoxib in arthritis: Relative risk management profile and implications for patients. Ther Clin Risk Manag. 2009;5:889–896
  18. Wiffen . Gabapentin for acute and chronic pain. Cochrane Database Syst Rev. 2005;3:CD001133
  19. Backonja M, Beydoun A, Edwards KR, et al. Gabapentin for the symptomatic treatment of painful neuropathy in patients with diabetes mellitus: A randomized controlled trial. J Am Med Assoc. 1998;280:1831–1836
  20. Rowbotham M, Harden N, Stacey B, et al. Gabapentin for the treatment of post-herpetic neuralgia: A randomized controlled trial. J Am Med Assoc. 1998;280:1837–1842
  21. Detrembleur C, De Nayer J, van den Hecke A. Celecoxib improves the efficiency of the locomotor mechanism in patients with knee osteoarthritis (A randomised, placebo, double-blind and cross-over trial). Osteoarthritis Cartilage. 2005;13:206–210
  22. Stern TA, Rosenbaum JF, Fava M, Biederman J, Rauch SL. Anticonvulsants, in Massachusetts General Hospital: Comprehensive Clinical Psychiatry. (ed 11). Philadelphia: Mosby-Elsevier; 2008;
  23. Bradley . Principles of pain management, in Neurology in Clinical Practice. Philadelphia: Elsevier; 2004;
  24. Max MB, Lynch SA, Muir J. Effects of desipramine, amitriptyline and fluoxetine on pain in diabetic neuropathy. N Engl J Med. 1992;326:1250–1256
  25. Pfizer: Lyrica (pregabalin) capsules prescribing information. New York, June 2007
  26. Dworkin RH, Corbin AE, Young JP, et al. Pregabalin for the treatment of postherpetic neuralgia: A randomized, placebo-controlled trial. Neurology. 2003;60:1274–1283
  27. Sabatowski R, Galvez R, Cherry DA, et al. Pregabalin reduces pain and improves sleep and mood disturbances in patients with post-herpetic neuralgia: Results of a randomised, placebo-controlled clinical trial. Pain. 2004;109:26–35
  28. Crofford LJ, Mease PJ, Simpson SL, et al. Fibromyalgia relapse evaluation and efficacy for durability of meaningful relief (FREEDOM): A 6-month, double-blind, placebo-controlled trial with pregabalin. Pain. 2008;136:419–431
  29. Lyseng-Williamson KA, Siddiqui MA. Pregabalin: A review of its use in fibromyalgia. Drugs. 2008;68:2205–2223
  30. Pregabalin (Lyrica) for fibromyalgia. Med Lett Drugs Ther. 2007;49:77–78
  31. Arnold LM, Russell IJ, Diri EW, et al. A 14-week, randomized, double-blinded, placebo-controlled monotherapy trial of pregabalin in patients with fibromyalgia. J Pain. 2008;9:792–805
  32. Wymer JP, Simpson J, Sen D, et al. Efficacy and safety of lacosamide in diabetic neuropathic pain: An 18-week double-blind placebo-controlled trial of fixed-dose regimens. Clin J Pain. 2009;25:376–385
  33. Wallace MS, Kudrow DB, McElveen WA, et al: Durect pharma: Clinical trial results: A randomized, double-blind, placebo-controlled, trial of three-day bupivicaine patch (Eladur) in patients with post herpetic neuralgia.
  34. Chong YY, Ng BY. Clinical aspects and management of fibromyalgia syndrome. Ann Academy Med Singapore. 2009;38:967–973
  35. Chong YY, Ng BY. Clinical aspects and management of fibromyalgia syndrome. Ann Academy Med Singapore. 2009;38:967–973
  36. Perucca E. Marketed new antiepileptic drugs: Are they better than old-generation agents?. Ther Drug Monit. 2002;24:74–80
  37. Ben-Menachem E, et al. Efficacy and safety of oral lacosamide as adjunctive therapy in adults with partial-onset seizures. Epilepsia. 2007;48:1308–1317
  38. Wallace, et al: Clinical Trial results: A randomized, double-blind, placebo-controlled, trial of a three day bupivicaine patch (Eladur) in patients with post-herpetic neuralgia. American Pain Society, 27th Annual Meeting, 2008
  39. Available at: http://www.durect.com/wt/durect/page_name/bupivacaine
  40. Available at: http://www.anesiva.com/wt/page/adlea
  41. Savella (milnacipran) package insert. St. Louis, MO: Forest, Pharmaceuticals, Inc; March 2009;
  42. Clauw DJ, Mease P, Palmer RH, et al. Milnacipran for the treatment of fibromyalgia in adults: A 15-week, multicenter, randomized, double-blind, placebo-controlled, multiple-dose clinical trial. Clin Ther. 2008;30:1988–2004
  43. Carville SF, Arendt-Nielsen S, Bliddal H, et al. EULAR evidence-based recommendations for the management of fibromyalgia syndrome. Ann Rheum Dis. 2008;67:536–541
  44. Mease PJ, Clauw DJ, Gendreau RM, et al. The efficacy and safety of milnacipran for treatment of fibromyalgia (A randomized, double-blind, placebo-controlled trial). J Rheumatol. 2009;36:398–409

PII: S1084-208X(10)00015-7

doi: 10.1053/j.trap.2010.03.001

Techniques in Regional Anesthesia & Pain Management
Volume 14, Issue 2 , Pages 75-85 , April 2010

Article Tools